夫西地酸对分枝杆菌的体外抑菌效果评价

doi:10.19982/j.issn.1000-6621.20230458

摘要/Abstract

摘要：

目的：评价夫西地酸(fusidic acid,FA)对分枝杆菌的体外抑菌效果。方法：选取首都医科大学附属北京胸科医院菌株库保存的分枝杆菌标准菌株和临床分离株作为研究菌株,其中,分枝杆菌标准菌株共计45株,包括26株快速生长型分枝杆菌(rapidly growing mycobacteria,RGM)菌株和19株缓慢生长型分枝杆菌(slowly growing mycobacteria,SGM)菌株;分枝杆菌临床分离株共计129株,为首都医科大学附属北京胸科医院2017年1月至2018年12月分离获得,包括结核分枝杆菌(Mycobacterium tuberculosis,MTB)药物敏感株26株、耐多药(multidrug-resistant,MDR)MTB菌株29株、广泛耐药(extensive drug-resistant,XDR)MTB菌株30株、鸟分枝杆菌分离株23株和戈登分枝杆菌分离株21株。采用肉汤稀释法药物敏感性试验,测定FA对研究菌株的最低抑菌浓度(minimum inhibitory concentration,MIC)、MIC₅₀、MIC₉₀、MIC₉₉,并将MIC≤16μg/ml的菌株定义为FA敏感株,分析菌株对FA的耐药情况。结果：RGM和SGM标准菌株对FA的耐药率分别为23.1%(6/26)和21.1%(4/19)。FA对MDR-MTB临床分离株的MIC₅₀、MIC₉₀、MIC₉₉分别是4、16、16μg/ml,MTB临床分离株对FA的耐药率为3.5%(3/85),其中MTB药物敏感株、MDR-MTB和XDR-MTB菌株的耐药率分别为0、0和10.0%(3/30)。鸟分枝杆菌和戈登分枝杆菌临床分离株对FA的耐药率分别为17.4%(4/23)和9.5%(2/21)。FA对分枝杆菌临床分离株的MIC₅₀、MIC₉₀、MIC₉₉值分别为4、16、>32μg/ml,分枝杆菌临床分离株对FA的总体耐药率为7.0%(9/129)。结论：FA对分枝杆菌菌种具有较强的抑菌活性,其中对MTB临床分离株具有很好的抑菌效果。

关键词: 分枝杆菌属, 微生物敏感性试验, 抗菌药, 体外研究, 夫西地酸

Abstract:

Objective: To evaluate the in vitro inhibitory activity of fusidic acid (FA) against mycobacteria. Methods: The standard strains and clinical isolates of mycobacteria stored in the strain bank of Beijing Chest Hospital, Capital Medical University were selected as the research strains. There were 45 standard strains of mycobacteria, including 26 rapidly growing mycobacteria (RGM) strains and 19 slowly growing mycobacteria (SGM) strains. A total of 129 clinical isolates of mycobacteria were isolated from Beijing Chest Hospital, Capital Medical University from January 2017 to December 2018, including 26 Mycobacterium tuberculosis (MTB) sensitive strains, 29 multidrug-resistant (MDR) strains, 30 extensive drug-resistant (XDR) strains, 23 Mycobacterium avium strains and 21 Mycobacterium gordon strains. Broth microdilution method was used to test the minimal inhibitory concentrations (MIC), MIC₅₀, MIC₉₀ and MIC₉₉ of mycobacteria strains against FA, and the strains with MIC ≤16μg/ml were defined as FA sensitive strains. The drug resistance of the strains to FA was analyzed. Results: The resistance rates of RGM and SGM standard strains to FA were 23.1% (6/26) and 21.1% (4/19), respectively. The MIC₅₀, MIC₉₀, and MIC₉₉ values of FA for MDR-MTB clinical isolates were 4, 16, and 16μg/ml, respectively. The resistance rate of MTB clinical isolates to FA was 3.5% (3/85), with the resistance rates of MTB drug sensitive strains, MDR-MTB, and XDR-MTB strains being 0, 0, and 10.0% (3/30), respectively. The resistance rates of clinical isolates of Mycobacterium avium and Mycobacterium gordon to FA were 17.4% (4/23) and 9.5% (2/21), respectively. The MIC₅₀, MIC₉₀, and MIC₉₉ values of FA for clinical isolates of mycobacterium were 4, 16, and >32μg/ml, respectively. The overall resistance rate of FA for clinical isolates of mycobacterium was 7.0% (9/129). Conclusion: FA has high antibacterial activity against mycobacterium species and has a good antibacterial effect on MTB clinical isolates.

Key words: Mycobacterium, Microbial sensitivity tests, Anti-bacterial agents, In vitro, Fusidic acid

中图分类号:

R378.91
R917

程梦丽, 姜广路, 霍凤敏, 薛毅, 于霞. 夫西地酸对分枝杆菌的体外抑菌效果评价[J]. 中国防痨杂志, 2024, 46(4): 461-466. doi: 10.19982/j.issn.1000-6621.20230458

Cheng Mengli, Jiang Guanglu, Huo Fengmin, Xue Yi, Yu Xia. Evaluation of in vitro activity of fusidic acid against mycobacteria[J]. Chinese Journal of Antituberculosis, 2024, 46(4): 461-466. doi: 10.19982/j.issn.1000-6621.20230458

图/表 2

表1

夫西地酸对26株快速生长型分枝杆菌标准菌株的最低抑菌浓度

菌株编号	拉丁文名称	中文名称	MIC(μg/ml)
ATCC 6841	Mycolicibacterium fortuitum	偶发分枝菌酸杆形菌	64.000
ATCC 23366	Mycolicibacterium aurum	金色分枝菌酸杆形菌	16.000
ATCC 25795	Mycolicibacterium neoaurum	新金色分枝菌酸杆形菌	0.250
ATCC 43909	Mycolicibacterium gilvum	浅黄分枝菌酸杆形菌	0.125
ATCC 19420	Mycolicibacterium smegmatis	耻垢分枝菌酸杆形菌	32.000
ATCC 19688	Mycolicibacterium parafortuitum	副偶发分枝菌酸杆形菌	8.000
ATCC 15483	Mycolicibacterium vaccae	母牛分枝菌酸杆形菌	1.000
ATCC 11758	Mycolicibacterium phlei	草分枝菌酸杆形菌	2.000
ATCC 19977	Mycobacterium abscessus	脓肿拟分枝杆菌	64.000
ATCC 27406	Mycolicibacterium agri	田野分枝菌酸杆形菌	0.250
ATCC 19527	Mycolicibacterium thermoresistibile	抗热分枝菌酸杆形菌	0.250
ATCC 43910	Mycolicibacterium duvalii	杜氏分枝菌酸杆形菌	0.125
ATCC 27024	Mycolicibacterium rhodesiae	罗德西亚分枝菌酸杆形菌	64.000
ATCC 33776	Mycobacterium porcinum	猪分枝杆菌	>64.000
ATCC 33464	Mycolicibacterium austroafricanum	南非分枝菌酸杆形菌	0.500
ATCC 35154	Mycolicibacterium pulveris	灰尘分枝菌酸杆形菌	1.000
ATCC 14472	Mycobacterium chelonae	龟拟分枝杆菌	16.000
ATCC 19627	Mycolicibacterium chitae	千田分枝菌酸杆形菌	0.500
DSM 43271	Mycolicibacterium peregrinum	外来分枝菌酸杆形菌	8.000
ATCC 700731	Mycolicibacterium septicum	败血症分枝菌酸杆形菌	4.000
DSM 44124	Mycolicibacterium mucogenicum	产黏液分枝菌酸杆形菌	1.000
ATCC BAA-955	Mycobacterium goodii	古德分枝杆菌	8.000
DSM 44829	Mycolicibacterium cosmeticum	美容品分枝菌酸杆形菌	>64.000
ATCC 27726	Mycolicibacterium gadium	加地斯分枝菌酸杆形菌	0.250
ATCC 27278	Mycolicibacterium chubuense	楚布分枝菌酸杆形菌	16.000
ATCC 27282	Mycolicibacterium tokaiense	东海分枝菌酸杆形菌	2.000

表1

表2

参考文献 18

[1]	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222. doi:10.1016/S0140-6736(20)30925-9.
[2]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis, 2020, 71(4): 905-913. doi:10.1093/cid/ciaa1125. pmid: 32797222
[3]	Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72 (Suppl 2): ii1-ii64. doi:10.1136/thoraxjnl-2017-210927.
[4]	Heidari H, Kalantari P, Sholeh M, et al. Trends in the antibiotic resistance of non-tuberculous mycobacteria in Iran: a syste-matic review and Meta-analysis. Iran J Public Health, 2023, 52(11): 2286-2298. doi:10.18502/ijph.v52i11.14028. pmid: 38106824
[5]	Furuuchi K, Morimoto K, Yoshiyama T, et al. Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan. Respir Med, 2019, 152: 74-80. doi:10.1016/j.rmed.2019.05.001. pmid: 31128614
[6]	Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med, 2015, 36(1): 13-34. doi:10.1016/j.ccm.2014.10.002. pmid: 25676516
[7]	Smith GS, Ghio AJ, Stout JE, et al. Epidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006—2010. J Infect, 2016, 72(6): 678-686. doi:10.1016/j.jinf.2016.03.008.
[8]	Godtfredsen W, Roholt K, Tybring L. Fucidin: a new orally active antibiotic. Lancet, 1962, 1(7236): 928-931. doi:10.1016/s0140-6736(62)91968-2. pmid: 13899434
[9]	Reeves DS. The pharmacokinetics of fusidic acid. J Antimicrob Chemother, 1987, 20(4): 467-476. doi:10.1093/jac/20.4.467.
[10]	Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis, 1997, 25(5): 1213-1221. doi:10.1086/516116. pmid: 9402384
[11]	Faber V, Dalgleish AG, Newell A, et al. Inhibition of HIV replication in vitro by fusidic acid. Lancet, 1987, 2(8563): 827-828. doi:10.1016/s0140-6736(87)91016-6. pmid: 2443777
[12]	Van Caekenberghe D. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. J Antimicrob Chemother, 1990, 26(3): 381-386. doi:10.1093/jac/26.3.381.
[13]	Pang Y, Zheng H, Tan Y, et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother, 2017, 61(5): e02627-16. doi:10.1128/AAC.02627-16.
[14]	Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute, 2011.
[15]	Cicek-Saydam C, Cavusoglu C, Burhanoglu D, et al. In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid. Clin Microbiol Infect, 2001, 7(12): 700-702. doi:10.1046/j.1469-0691.2001.00341.x.
[16]	Fuursted K, Askgaard D, Faber V. Susceptibility of strains of the Mycobacterium tuberculosis complex to fusidic acid. APMIS, 1992, 100(7): 663-667. doi:10.1111/j.1699-0463.1992.tb03983.x. pmid: 1642855
[17]	Hoffner SE, Olsson-Liljequist B, Rydgård KJ, et al. Susceptibility of mycobacteria to fusidic acid. Eur J Clin Microbiol Infect Dis, 1990, 9(4): 294-297. doi:10.1007/BF01968066.
[18]	Witzig RS, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother, 1993, 37(9): 1997—1999. doi:10.1128/AAC.37.9.1997.

菌株编号	拉丁文名称	中文名称	MIC(μg/ml)
ATCC 27294	Mycobacterium tuberculosis (H37Rv)	结核分枝杆菌	4
	Mycobacterium tuberculosis (H37Ra)	结核分枝杆菌	1
ATCC 12478	Mycobacterium kansassi	堪萨斯分枝杆菌	16
ATCC 13950	Mycobacterium intracellulare	胞内分枝杆菌	32
ATCC 19530	Mycobacterium nonchromogenicum	不产色分枝菌酸杆形菌	16
ATCC 25291	Mycobacterium avium	鸟分枝杆菌	8
ATCC 19981	Mycobacterium scrofulaceum	瘰疬分枝杆菌	16
ATCC 23292	Mycobacterium triviale	次要分枝菌酸小杆菌	32
ATCC 19210	Mycobacterium tuberculosis variant bovis	结核分枝杆菌牛变种	4
ATCC 25276	Mycobacterium asiaticum	亚洲分枝杆菌	8
DSM 44622	Mycobacterium chimaera	胞内分枝杆菌奇美拉亚种	16
DSM 44243	Mycobacterium celatum	隐蔽分枝杆菌	32
DSM 44648	Mycobacterium parascrofulaceum	副瘰疬分枝杆菌	32
ATCC 33013	Mycolicibacterium komossense	科莫斯分枝菌酸杆形菌	4
ATCC 19619	Mycolicibacter terrae	土分枝菌酸杆菌	8
ATCC 25799	Mycobacterium szulgai	苏尔加分枝杆菌	16
ATCC 27962	Mycobacterium shimoidei	施氏分枝杆菌	8
ATCC 14470	Mycobacterium gordonae	戈登分枝杆菌	2
ATCC 35711	Mycobacterium tuberculosis variant africanum	结核分枝杆菌非洲变种	2